Reports and Briefs on Therapy Area in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Product Profiles: Psoriasis – Novel therapies raise the bar for biologics

This report analyzes key marketed and pipeline agents for psoriasis, including the current market dynamics of topical, oral and biologic products, key lifecycle management strategies, as well as clinical trial data from 2011 dermatology conferences.

Published By Datamonitor
23 Nov 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor

Datamonitor forecasts sales of leading antidyslipidemic brands and pipeline products. Coverage: US, Japan, France, Germany, Italy, Spain, and the UK

Published By Datamonitor
23 Nov 2011 $6400
Buy
Report
Report

Market and Product Forecast: Osteoporosis - Prolia and odanacatib to restore growth in the market

Osteoporosis drug forecast sales trends up to 2020 across the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK). The analysis is designed to understand the future dynamics of the osteoporosis prescription market.

Published By Datamonitor
01 Nov 2011 $6400
Buy
Report
Report

Prescribing Influences: Type 2 Diabetes – Opportunities in type 2 diabetes for drugs with both safety and efficacy

Datamonitor reports physician perceptions and key opinion leader insight into unmet needs in type 2 diabetes, as well as how well marketed and late-stage pipeline classes perform in key influencing criteria for prescribing choice.

Published By Datamonitor
29 Sep 2011 $2800
Buy
Report
Report

Market and Product Forecasts: Neuropathic Pain - Targeting underserved indications drives market growth

This report assesses the current and future neuropathic market accounting for the latest market events. The analysis is designed to understand the future dynamics of the neuropathic pain drug market.

Published By Datamonitor
14 Sep 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market

Focusing on disease-modifying drugs, Datamonitor uses a patient-based approach to size the seven major rheumatoid arthritis markets from 2010 to 2020. Robust epidemiology forecasts, survey data and opinion leader discussions validate key assumptions.

Published By Datamonitor
08 Sep 2011 $6400
Buy
Report
Report

Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

Analysis of current market dynamics for the treatment of prostate cancer. The report assesses comparator therapies for prostate cancer, identifies key strategies for drug development, and analyzes commercial and clinical potential of pipeline drugs.

Published By Datamonitor
02 Sep 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Systemic Lupus Erythematosus – Benlysta approval kicks off new era in lupus treatment

Benlysta’s US and EU approvals will change the lupus market considerably. With additional products moving through the pipeline, Datamonitor expects to see a significant shift from off- to on-label treatment over the next 10 years.

Published By Datamonitor
22 Aug 2011 $6400
Buy
Report
Report

Prescribing Influences: Multiple Sclerosis - Therapies that reverse neuronal damage are most sought after

This report analyzes the unmet needs of multiple sclerosis treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
09 Aug 2011 $2800
Buy
Report
Report

Key Companies: Depression - Leading players must adapt to remain competitive

This report identifies the leading players that are active in the depression pharmaceutical market, evaluating trends in corporate strategy and discussing the impact of key recent licensing deals.

Published By Datamonitor
02 Aug 2011 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.